BioMarin PharmaceuticalMEX:BMRN 80 PE Ratio without NRI is 18.65 as of Jul. 03, 2026, which is 34% below its 10-year median of 28.16. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,495.95 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 267 Biotechnology companies, BioMarin Pharmaceutical ranks better than 59.18% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-03), BioMarin Pharmaceutical's share price is MXN959.00.
BioMarin Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN51.30. Therefore, BioMarin Pharmaceutical's PE Ratio without NRI for today is 18.65.
During the past 13 years, BioMarin Pharmaceutical's highest PE Ratio without NRI was 622.24. The lowest was 12.24. And the median was 28.16.
BioMarin Pharmaceutical (MEX:BMRN) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
BioMarin Pharmaceutical PE Ratio without NRI Related Terms
BioMarin Pharmaceutical PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical PE Ratio without NRI Chart
MEX:BMRN vs CYTK, ARWR, TECH: PE Ratio without NRI Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's PE Ratio without NRI falls into.
BioMarin Pharmaceutical PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
BioMarin Pharmaceutical's Share Price of today is MXN959.00.
BioMarin Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN51.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
BioMarin Pharmaceutical (MEX:BMRN) has a PE Ratio without NRI of 18.65 as of Jul. 03, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on BioMarin Pharmaceutical and its competitors. This is 34% below median its historical median of 28.16. Over the past decade, BioMarin Pharmaceutical's PE Ratio without NRI has ranged from 12.24 to 622.24. According to the industry distribution chart, BioMarin Pharmaceutical ranks #109 out of 267 companies in the Biotechnology industry, placing it in the top 40.8%.
Is BioMarin Pharmaceutical's PE Ratio without NRI too high?
BioMarin Pharmaceutical's current PE Ratio without NRI of 18.65 is 34% below median its 10-year median of 28.16. Over the past 10 years, this metric has ranged from a low of 12.24 to a high of 622.24. The Biotechnology industry median PE Ratio without NRI is 25.64. BioMarin Pharmaceutical's value of 18.65 is 27.3% below this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #109 out of 267 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's PE Ratio without NRI compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #109 out of 267 companies for PE Ratio without NRI. This puts BioMarin Pharmaceutical in the upper half of its industry. The industry median PE Ratio without NRI is 25.64. BioMarin Pharmaceutical's value of 18.65 is 27.3% below this benchmark. Historically, BioMarin Pharmaceutical's own PE Ratio without NRI has ranged from 12.24 to 622.24 over the past decade. While the company's 10-year median is 28.16 vs. the industry median of 25.64, BioMarin Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.64, based on 267 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current PE Ratio without NRI of 18.65 is 27.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current PE Ratio without NRI is 18.65, which is 34% below median its own 10-year median of 28.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,495.95, compared to a current price of MXN959.00 — trading 35.9% below its estimated fair value. The current PE Ratio without NRI is 18.65, which is 34% below median its 10-year median of 28.16 and 27.3% below the Biotechnology industry median of 25.64. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current PE Ratio without NRI is 18.65 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 35.9% below its estimated GF Value™ of MXN1,495.95.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
PE Ratio without NRI: 18.65 (34% below median its 10-year median of 28.16)
GF Value™: MXN1,495.95 vs. price of MXN959.00 (35.9% below fair value)
Industry Position: 27.3% below the Biotechnology median (#109 of 267)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
